Laekna, Inc. (02105.HK)

Laekna, Inc. engages in the provision of clinical stage research and development of biopharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 84 full-time employees. The company went IPO on 2023-06-29. The firm is still in the research and development stage. The firm's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The firm mainly conducts business in the Chinese, America, European, Korean, and other markets.